GSK690693
Sponsors
GlaxoSmithKline
Conditions
Cancer
Phase 1
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
TerminatedNCT00493818
Start: 2007-04-30End: 2008-06-30Target: 70Updated: 2017-01-18
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
WithdrawnNCT00666081
Start: 2008-04-30End: 2009-12-31Updated: 2015-04-17